User Fees For Biomarker Qualification Might Improve Study Designs
Executive Summary
Despite Bob Temple’s assurance that draft enrichment guidance allows companies to exclude biomarker-negative patients, industry asks FDA for more guidance on when they can safely say a biomarker is discriminatory.